CClinicalTrials.gg
CompletedNCT01057511Updated Apr 3, 2012

Compare the Difference of P4 Concentration in Serum and Endometrium After Vaginal and IM P Administration

A Phase 1/2 interventional study of Crinone 8% and Progesterone in Postmenopausal Endometrium, sponsored by Peking Union Medical College Hospital. Completed at 1 site in China. Open to female participants aged Up to 55 Years. Per ClinicalTrials.gov, last updated 2012-04-03.

Sponsored by Peking Union Medical College Hospital · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
Up to 55 Years
Sex
Female
01

Study summary

Crinone is a micronized progesterone gel which is administrated via vaginal route and targeted drug delivery to uterine (first uterine pass effect) with lower serum concentration. This study is to investigate the difference of progesterone concentration in serum and endometrium after administration with crinone and intramuscular progesterone.

The study will be conducted as a single centre, randomized, active controlled study. Recruitment duration will be 6-8 months long. Day 1 of Crinone administration will be the baseline. On Day 7 of Crinone administration endometrial tissue will be taken for P4 test. Last visit will be at 3-5 days after withdraw bleeding.

02

Conditions studied

  • Postmenopausal Endometrium

Keywords

  • Crinone
  • progesterone
  • endometrial progesterone concentration
03

In context

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,115 studies on the registry; 463 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Perimenopausal women aged \<55 years old with amenorrhea>=2 months or reproductive aged women with amenorrhea >= 6months due to premature ovarian failure or other reasons.;
  • Serum progesterone level \< 1ng/mL
  • Endometrial thickness ≥5mm
  • No contraindication of progesterone administration;
  • Informed consent is signed.

Exclusion criteria

Exclusion Criteria:

  • The other kind of progestin was applied 1 month before recruitment;
  • Any serious diseases that does not allow to receive the progestin treatment;
  • Under any vaginal treatment;
  • Any vaginal infectious disease;
  • Any other hormone treatment contraindications;
  • drug abuse or untreated STD;
  • Prior hypersensitivity to Crinone or one of their excipients.
  • Pregnant women who indicate hCG positive.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
51 participants (actual)

Study arms

  • Active comparator
    progesterone

    Each subject in this group will be give progesterone oil 20mg via intramuscular route once a day for 7 days totally

    Drug: Progesterone

  • Experimental
    Crinone 8%

    Each subjects in this group will be given Crinone 8% 90mg via vaginal route once a day for 7 days totally.

    Drug: Crinone 8%

Interventions

  • DrugCrinone 8%

    Crinone 8%, 90mg / p.v. / Qd, 7 days totally.

    Also known as: progesterone vaginal gel

  • DrugProgesterone

    Progesterone 20mg/ i.m./ Qd, 7 days totally.

    Also known as: IMP

06

What researchers measure

Primary outcomes

  1. Primary endpoint: progesterone level in endometrium and in serum

    The women who singed informed consent were randomized into two groups, respectively received Crinone 90mg via vaginal route or progesterone 20mg via IM route, once per day, for seven days. After 7 days therapy, endometrium biopsy was taken via vaginal route for tissue P concentration test by radioimmunoassay method. Blood sample were drawn for serum progesterone level.

    Time frame: after 7 days of progesterone therapy

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, 100730, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01057511
Lead sponsor
Peking Union Medical College Hospital
Collaborators
Merck Serono International SA
Responsible party
Sponsor
First posted
Jan 27, 2010
Start date
Dec 2009
Primary completion
Aug 2011
Completion
Feb 2012
Last update
Apr 3, 2012

Study contacts

AIJUN SUN, PhD, MD
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion